RxDoctor Payments Data

Alina Dobrita, MD

Family Medicine · Avon, CTNPI 1194945063

Payments from drug & device makers

$305in general payments, 2019–2025

Across 18 payments — averaging $16.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$62
  • Novo Nordisk$59
  • MDD US Operations, LLC$49
  • Merck$40
  • Pfizer$28
  • Lilly USA, LLC$16
  • plus $51 from 4 others

What the payments were for

  • Food & beverage$24380%
  • Education$6220%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$305 in reported general payments places this provider in the 50th percentile of 588 family medicine providers in Connecticut.

See all family medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$91,470
Medicare patients
225
Services billed
1,122

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban54$57,946
JardianceEmpagliflozin48$56,962
JanuviaSitagliptin Phosphate29$47,923
MounjaroTirzepatide30$43,298
OzempicSemaglutide38$39,742
FarxigaDapagliflozin Propanediol17$29,240
XareltoRivaroxaban17$22,009
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr26$16,638
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$15,845
TradjentaLinagliptin12$13,788
JanumetSitagliptin Phos/Metformin Hcl15$11,923
Rosuvastatin Calcium805$9,402
Breo ElliptaFluticasone/Vilanterol14$9,341
SynthroidLevothyroxine Sodium68$6,482
Ezetimibe174$4,311

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet$40$59,84644 claims
PfizerEliquis, Paxlovid$28$59,37583 claims
Lilly USA, LLCMounjaro$16$43,29830 claims
GSKAnoro Ellipta, Trelegy Ellipta, Breo Ellipta$12$41,82464 claims
Novo NordiskOzempic$59$39,74238 claims
AstraZenecaFarxiga$62$29,24017 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 588 family medicine providers in Connecticut.

Other family medicine in Avon

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →